2025-04-05 - Analysis Report
## Teva Pharmaceutical Industries Ltd ADR (TEVA) Stock Review

**0. Key Figures & Initial Analysis:**

TEVA's cumulative return significantly underperformed the S&P 500 (VOO) over the observed period.  While TEVA showed a cumulative return of 37.4%, VOO achieved 71.0%, resulting in a substantial negative divergence. The relative divergence of -33.6% indicates that TEVA's performance lagged behind the S&P 500,  placing it in the lower percentile of its historical performance relative to the index (65.5% on a relative scale).  Further analysis is needed to determine the drivers behind this underperformance.

**1. Performance Comparison & Company Overview:**

Teva Pharmaceutical Industries Ltd ADR (TEVA) is a global pharmaceutical company.

| Metric           | TEVA                  | VOO                   | Difference | Relative Divergence |
|--------------------|-----------------------|------------------------|-------------|----------------------|
| Cumulative Return | 37.4%                 | 71.0%                 | -33.6%      | 65.5% (Lower Percentile) |


**Alpha & Beta Analysis:**

The provided data shows inconsistent performance across different periods.  Alpha consistently remains negative, indicating underperformance relative to the market (as represented by the S&P 500). Beta fluctuates, suggesting varying levels of market sensitivity.  The high beta values in some periods point to increased volatility compared to the overall market.  The market cap shows variability, possibly reflecting changes in investor sentiment and market conditions.


| Year       | CAGR   | MDD    | Alpha | Beta  | Cap(B) |
|------------|--------|--------|-------|-------|--------|
| 2015-2017  | -44.0% | 58.0% | -74.0% | 0.0   | 22.1   |
| 2016-2018  | -41.0% | 69.7% | -58.0% | -0.1  | 18.0   |
| 2017-2019  | -16.0% | 69.7% | -45.0% | -0.2  | 11.4   |
| 2018-2020  | 7.0%   | 69.7% | -23.0% | -0.2  | 11.2   |
| 2019-2021  | -18.0% | 54.3% | -92.0% | -0.2  | 9.3    |
| 2020-2022  | 29.0%  | 74.8% | 9.0%  | -0.2  | 10.6   |
| 2021-2023  | 33.0%  | 74.8% | 5.0%  | -1.4  | 12.2   |
| 2022-2024  | 123.0% | 74.8% | 108.0%| -1.3  | 25.7   |
| 2023-2025  | 43.0%  | 79.4% | 40.0% | -0.9  | 16.1   |


**2. Recent Price Movement:**

TEVA's recent price action shows a downward trend. The closing price is below all three moving averages (5-day, 20-day, and 60-day), indicating bearish momentum.

* **Closing Price:** $13.80
* **5-Day MA:** $14.92
* **20-Day MA:** $15.73
* **60-Day MA:** $17.43
* **Last-market Change:** -7.07% (significant daily drop)


**3. Technical Indicators & Expected Return:**

The RSI (10.14) is extremely low, suggesting the stock is oversold. The negative PPO (-0.75) further reinforces the bearish sentiment. The recent increase in relative divergence (+2.9) points to a short-term upward trend, potentially a temporary bounce.  The Market Risk Indicator (MRI) of 0.4693 falls into the High Risk category, suggesting caution. The significant daily price drop (-7.07%) indicates a possible sharp market reaction to negative news.  The expected return of -46.1% signifies a high risk of further decline;  the long-term (2+ years) expected return relative to the S&P 500 is likely to remain negative given the current indicators.

**4. Recent Earnings Analysis:**

Recent earnings show inconsistent profitability, with both positive and negative EPS figures. Revenue generally shows stability.  The negative EPS figures in several quarters might explain some of the negative investor sentiment.

| Date       | EPS    | Revenue     |
|------------|--------|-------------|
| 2024-11-06 | -$0.39 | $4.33B      |
| 2024-07-31 | -$0.75 | $4.16B      |
| 2024-05-08 | -$0.12 | $3.82B      |
| 2023-11-09 | $0.07  | $3.85B      |
| 2024-02-12 | $0.06  | $3.85B      |


**5. Financial Information:**

Revenue has remained relatively stable, while profit margins have fluctuated, decreasing in recent quarters.  Equity has decreased, and ROE is negative in recent quarters, indicating a decline in profitability and potentially raising concerns about the company's financial health.  The sharp drop in ROE from positive territory in 2023-12-31 to negative territory in subsequent quarters is a significant warning sign.

**Revenue and Profitability:**

| Quarter     | Revenue | Profit Margin |
|-------------|----------|---------------|
| 2024-12-31 | $4.23B  | 50.15%        |
| 2024-09-30 | $4.33B  | 49.60%        |
| 2024-06-30 | $4.16B  | 48.61%        |
| 2024-03-31 | $3.82B  | 46.37%        |
| 2023-12-31 | $4.46B  | 54.18%        |


**Capital and Profitability:**

| Quarter     | Equity  | ROE     |
|-------------|---------|---------|
| 2024-12-31 | $5.37B  | -4.04%  |
| 2024-09-30 | $6.07B  | -7.21%  |
| 2024-06-30 | $6.36B  | -13.30% |
| 2024-03-31 | $7.28B  | -1.91%  |
| 2023-12-31 | $7.51B  | 5.72%   |


**6. Overall Conclusion:**

TEVA is currently exhibiting several negative indicators: significant underperformance relative to the S&P 500, low RSI and negative PPO suggesting oversold conditions, negative alpha indicating consistent underperformance relative to the market, fluctuating beta implying substantial market risk, and declining ROE. Recent earnings show mixed results, and the sharp decrease in equity and ROE raises serious concerns about the company's financial health.  While a short-term bounce is possible, given the current bearish trend, substantial risk exists.  Investing in TEVA requires a high-risk tolerance and thorough due diligence to understand the underlying reasons for the company's underperformance.  A long-term investment strategy should carefully consider the negative expected return relative to the S&P 500.
